[go: up one dir, main page]

NO20003775L - FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner - Google Patents

FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Info

Publication number
NO20003775L
NO20003775L NO20003775A NO20003775A NO20003775L NO 20003775 L NO20003775 L NO 20003775L NO 20003775 A NO20003775 A NO 20003775A NO 20003775 A NO20003775 A NO 20003775A NO 20003775 L NO20003775 L NO 20003775L
Authority
NO
Norway
Prior art keywords
heat shock
inflammatory diseases
treating inflammatory
shock proteins
response
Prior art date
Application number
NO20003775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003775D0 (no
Inventor
Erwin W Gelfand
Angela Francisca Haczku
Katalin Veronika Lukacs
Original Assignee
Nat Jewish Med & Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Med & Res Center filed Critical Nat Jewish Med & Res Center
Publication of NO20003775D0 publication Critical patent/NO20003775D0/no
Publication of NO20003775L publication Critical patent/NO20003775L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20003775A 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner NO20003775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
PCT/US1999/001421 WO1999037319A1 (fr) 1998-01-23 1999-01-22 Methode de traitement des maladies inflammatoires utilisant des proteines du stress

Publications (2)

Publication Number Publication Date
NO20003775D0 NO20003775D0 (no) 2000-07-21
NO20003775L true NO20003775L (no) 2000-09-22

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003775A NO20003775L (no) 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Country Status (16)

Country Link
US (2) US20020006410A1 (fr)
EP (1) EP1049483A1 (fr)
JP (1) JP2002509074A (fr)
KR (1) KR20010040389A (fr)
CN (1) CN1324243A (fr)
AU (1) AU2337499A (fr)
BR (1) BR9907228A (fr)
CA (1) CA2318263A1 (fr)
CZ (1) CZ20002669A3 (fr)
HU (1) HUP0100241A2 (fr)
IL (1) IL137404A0 (fr)
NO (1) NO20003775L (fr)
PL (1) PL342166A1 (fr)
TR (1) TR200002973T2 (fr)
WO (1) WO1999037319A1 (fr)
ZA (1) ZA99499B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
WO2000048622A2 (fr) * 1999-02-22 2000-08-24 University Of Iowa Research Foundation Methode permettant l'inhibition de reactions inflammatoires
AU7729000A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Modulation of gammadelta t cells to regulate airway hyperresponsiveness
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1551957A4 (fr) * 2001-10-01 2007-01-24 Univ Duke Polypeptide de domaine de liaison au ligand grp94 isole et acide nucleique codant pour celui-ci, forme cristalline de ce polypeptide et technique de recherche utilisant ce polypeptide
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
CA2626692A1 (fr) * 2005-10-20 2007-04-26 Cbio Limited Traitement de l'hypersensibilite
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
WO2009155936A1 (fr) 2008-06-26 2009-12-30 Orphazyme Aps Utilisation du hsp70 en tant que régulateur de l'activité enzymatique
EP2391229B1 (fr) 2009-01-29 2015-07-15 Alfa Biogene International B.V. Produit alimentaire fonctionnel comprenant une protéine de choc thermique de luzerne ou un hydrolysat de celle-ci
EP2397074B1 (fr) * 2010-06-19 2012-10-24 M Stenqvist AB Système et support lisible par ordinateur stockant un programme pour déterminer la pression transpulmonaire chez un patient connecté à un appareil respiratoire
JP2013544263A (ja) 2010-11-30 2013-12-12 オルファザイム エーピーエス Ｈｓｐ７０の細胞内活性を上昇させる方法
WO2012097255A2 (fr) * 2011-01-14 2012-07-19 Scott & White Healthcare Effet thérapeutique de protéines de choc thermique utilisées pour la prévention de l'agrégation de l'amyline dans le diabète sucré de type 2
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
WO2012174549A2 (fr) * 2011-06-16 2012-12-20 Children's Hospital Medical Center Blocage de production d'éosinophiles par des récepteurs de type toll
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
CA2861464C (fr) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Activite du proteasome modulant les composes tricycliques
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP3402572B1 (fr) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions et méthodes de traitement d'états inflammatoires allergiques
WO2017178029A1 (fr) 2016-04-13 2017-10-19 Orphazyme Aps Protéines de choc thermique et homéostasie du cholestérol
CN109069496A (zh) 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019204580A1 (fr) 2018-04-20 2019-10-24 Children's Hospital Medical Center Biomarqueur sanguin pour troubles gastro-intestinaux éosinophiliques
EP3814336A1 (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
MA53014A (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics Inc Composés améliorant l'activité du protéasome
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
DE69126668T2 (de) * 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
WO1998023735A1 (fr) * 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Reponses immunes mettant en oeuvre des compositions contenant des proteines de stress

Also Published As

Publication number Publication date
US20070179087A1 (en) 2007-08-02
HUP0100241A2 (hu) 2001-06-28
PL342166A1 (en) 2001-05-21
CZ20002669A3 (cs) 2001-11-14
US20020006410A1 (en) 2002-01-17
CN1324243A (zh) 2001-11-28
CA2318263A1 (fr) 1999-07-29
TR200002973T2 (tr) 2001-02-21
EP1049483A1 (fr) 2000-11-08
IL137404A0 (en) 2001-07-24
NO20003775D0 (no) 2000-07-21
ZA99499B (en) 1999-07-22
BR9907228A (pt) 2000-10-24
AU2337499A (en) 1999-08-09
WO1999037319A1 (fr) 1999-07-29
KR20010040389A (ko) 2001-05-15
JP2002509074A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
NO20003775L (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
NO991784D0 (no) Purin-L-nukleosider, analoger og anvendelser derav
ATE228373T1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
NL194940B (nl) Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.
EA199700413A1 (ru) Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
NO832630L (no) Trifenylimidazolyloxyalkansyrer og deres derivater, deres fremstilling og deres anvendelse i preparater
WO1996012794A3 (fr) Cellules pancreatiques porcines isolees pour le traitement de troubles caracterises par une activite insuffisante de l'insuline
NO931372D0 (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
DK1733730T3 (da) Immunmodulerende oligosaccharider
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
WO1996013512A3 (fr) Nucleosides de l-ribofuranosyle
DK1009413T3 (da) Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
ES2192839T3 (es) Timosina beta 4 oxidada.
NO881515L (no) Pulmonar surfaktant.
WO1999032634A3 (fr) Compositions derivees de mycobacterium vaccae et leurs methodes d'utilisation
EP0593290A3 (fr) Proteine antigènique du noyau du virus de l'hépatite C, et méthode diagnostiquée et nécessaire.
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application